Study Says Bayer's Trasylol Safe For Some Patients

Law360, New York (February 13, 2008, 12:00 AM EST) -- A new study has found that Bayer AG's blood-clotting drug Trasylol, which has been suspected of causing kidney damage and death in some cases, appears to be safe for some heart patients.

The study was published Thursday by a team of British researchers in the United Kingdom-based medical journal The Lancet. It determined that Trasylol, also known as aprotinin, appeared to pose little risk for people undergoing on-pump bypass surgery, in which a machine keeps the patient's heart beating during the operation.

However, the risk of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.